Aiforia Technologies Oyj Poised for Growth in Clinical Segment

Aiforia Technologies Oyj has demonstrated significant growth in its clinical segment, as reported in their H2’25 results. Net sales rose by 45% year-over-year (yoy) to €2.1 million, with the clinical segment experiencing a 68% increase to €1.5 million. This growth is attributed to a larger share of wallet among existing clients and successful clinical tender wins.

The company's EBITDA showed improvement, rising from € -4.0 million to € -3.0 million, influenced by operational leverage and reduced personnel expenses. Cash reserves stood at €9.5 million, affected by working capital and capital expenditure requirements.

Aiforia's strategic shift toward pay-per-use clinical contracts and partnerships, including with Siemens Healthineers, positions it for accelerated growth. The company targets a 70% net sales increase to €6.0 million in FY26, sustaining its positive trajectory.